Detect low levels of innate immune response

The Epibase® Dendritic Cell Activation Assay uses human dendritic cells (DC) to assess the impact of your biotherapeutic protein on the innate immune response. Similar to the Epibase® Cytokine Release Assay, cytokine/chemokine profiles are assessed after incubation of the DC with the test biotherapeutic protein.The assay has been designed to detect very low levels of innate immune response modulating impurities (IIRMIs) present in the sample which may impact the safety and immunogenicity of the product.

Dendritic Cell Activation Assay

  • Resting Dendritic cells (DC) are generated from healthy donors and loaded with test protein
  • DC phenotype is assessed before and after treatment with the protein by flow cytometry (DC viability and key DC activation markers)
  • Supernatant samples are analyzed for the secretion of key DC cytokines/chemokines by Luminex®
  • Standard cytokine/chemokine panel includes: FGF basic, Eotaxin, G-CSF, GM-CSF, IFNγ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNFα, VEGF
  • Customized cytokine/chemokine panels can also be created on demand
  • LPS (lipopolysaccharide) is included as a typical control and potent activator of DC cytokine expression